Summary In an attempt to develop an assay to predict patient tumour response to cyclophosphamide (CP), the feasibility of using a glutathione-targeted assay to assess the in vitro chemosensitivity of tumour cells to 4-hydroperoxylcyclophosphamide (4-OOH-CP), an activated congener of CP, was evaluated. A panel of 19 human and three murine tumour cell lines was used. These consisted of three main categories of tumour types, viz. ovarian, lung and squamous cell carcinoma. The major finding was that the occurrence of a significant reduction of tumour cell reproductive capacity was always accompanied by substantial depletion of cellular glutathione (GSH) content, and vice versa. Plots of % GSH depletion versus clonogenic cell survival demonstrated highly significant correlation (r=0.90-0.91; P<0.01). It was determined that for in vitro tumour cell lines, a GSH depletion to 40% of initial content may serve as a cut-off criterion for chemosensitivity to 4-OOH-CP. This degree of GSH depletion is indicative of clonogenic cell survival of approximately 1% (95% confidence limits = 3 x 10-5-1.6 x 10-2). The relationship between steady state GSH content and intrinsic sensitivity to 4-OOH-CP was also evaluated. The GSH concentration of the tumour cell lines ranged from 1.3-21.2 x 10-i8 moles lm-3; chemosensitivity to 4-OOH-CP, in terms of IC99, was in the range of 5.0 -87.1IM. A good correlation was observed between these two parameters (r = 0.85, P <0.02). These results suggest that GSH plays an important role in determining the therapeutic efficacy of 4-OOH-CP in the treatment of cancer. It is uncertain, however, whether a high tumour steady state GSH content in itself is sufficient to cause therapeutic failure in patients.
Cyclophosphamide (CP) and its congeners are among the most efficacious and frequently used agents for the treatment of human malignancies. The pharmacology and metabolic fate of CP has been extensively studied and is now relatively well understood (Sladek, 1987) . When given systemically, CP is metabolised, through hydroxylation by the hepatic mixedfunction oxidases, to 4-hydroperoxycyclophosphamide (4-OH-CP), a 'transport' form of CP which exists in equilibrium with its ring-opened tautomer aldophosphamide (AP). Glutathione (GSH) can participate in conjugative reactions at two separate locations in the cyclophosphamide metabolic pathway that may exert considerable influence on the eventual cytotoxicity of the cytotoxic agent (see Figure I of the accompanying paper (Lee, 1990) and others Gurtoo et al., 1981) ). (1) GSH reacts with AP to form 4-OH-CP and shifts the tautomerism pseudo-equilibrium between 4-OH-CP and aldophosphamide (AP) in favour of the former tautomer Lee, 1990) . (2) GSH binds irreversibly to the toxic metabolites of 4-OH-CP, in particular acrolein (Gurtoo et al., 1981) . Because of these reactions, exposure of cells to 4-OH-CP may lead to depletion of endogenous GSH if the combined rates of the conjugation reactions exceed the rate of GSH recovery. In fact, a number of studies, all using high and therefore toxic doses of CP, have already shown that CP depletes cellular GSH level in vivo (Adams et al., 1986; Carmichael et al., 1986) and in vitro (Crook et al., 1986) . Recently, in a series of experiments in which both GSH status and cytotoxicity were determined in the same tumour cell population, we observed that toxic concentrations of 4-OOH-CPt severely depleted tumour cells of GSH whereas nontoxic concentrations of 4-OOH-CP produced no such effect (Siemann et al. in preparation) . Furthermore, a tumour cell type (KHT) highly susceptible to GSH depletion by 4-OOH-CP was also found to be highly sensitive to this agent while a tumour cell line (A549) resistant to GSH depletion by 4-OOH-CP was shown also to be refractory to the drug's cytotoxic effects. The present study was therefore designed to: (1) establish in detail the relationship between 4-OOH-CP induced GSH depletion and cytotoxicity and (2) determine whether measurements of the extent of GSH depletion induced by clinically relevant concentrations of 4-OOH-CP can be used to predict for tumour response to this anticancer agent.
Materials and methods
Cell culturing Three major categories of human tumour cell lines were used in this study: ovarian, lung and squamous cell carcinomas. The ovarian cell lines, except SKOV-3, CaOV-3 and NIH: OVCAR-3, were established from biopsy specimens (Lee et al., 1989) . SKOV-3, CaOV-3 and NIH:OVCAR-3 were obtained from the American Type Culture Collection. The small cell lung line POC was received from Dr P. Twentyman. The other lung lines were obtained from Dr J. Mitchell courtesy of Dr J. Minna. Three epidermoid cell lines were also used in this study. They were HEp3 derived from a metastatic buccal mucosa carcinoma (Toolan, 1954) , A431 derived from a vulva carcinoma (Giard et al., 1973) , and ME180 derived from a cervix carcinoma (Sykes et al., 1970) . Limited studies with the rodent KHT sarcoma cell line (Kallman et al., 1967) were performed. Culture conditions, growth characteristics and plating efficiency for the human tumour cell lines are listed in Table I . All nutrient media and sera were obtained from Gibco Laboratories (Grand Island, NY) . Cell cultures were maintained at 37'C under an atmosphere of 5% C02/95% air. All cell lines, except POC, grew as monolayers and were routinely subcultured every 3 to 4 days with standard trypsinisation procedures using Worthington's trypsin (Worthington Biochemical Corp, New Jersey, USA). Clonogenic assays were performed with exponentially growing cells 2 to 3 days after seeding.
t4-OOH-CP gives rise rapidly to 4-OH-CP following dissolution without any enzymic involvement and may be regarded as equivalent to 4-OH-CP pharmacologically (Sladek, 1987 OVAC, ovarian adenocarcinoma; LAC, lung adenocarcinoma; LSqC, lung squamous carcinoma; LCLC, large cell lung cancer; SCLC, small cell lung cancer; EpC, epidermoid squamous carcinoma; BCa, breast carcinoma; MFSa, murine fibrosarcoma; CHO, Chinese hamster ovary; FCS, foetal calf serum; TD, population doubling time; CFE, colony-forming efficiency. Therapy received before establishment of cell line: c, cyclophosphamide; A, adriamycin; P, cisplatin; F, 5-fluorouracil; M, melphalan; Mx, methotrexate; Tf, tamoxifen; T, thiotepa; N.A., information not available.
Drug preparation and treatment For drug treatment, cells were trypsinised and a single-cell suspension at 2.5 x IO' cells ml-' in complete medium was placed in a type I vial at 37°C and continuously gassed with a 5% C02/95% air gas mixture as previously described (Whillans & Rauth, 1980; Siemann et al., 1989) . Cells were allowed to equilibrate at these conditions for 30 min prior to drug exposure. Drug treatment was for a 3 h period.
4-hydroperoxycyclophosphamide (4-OOH-CP) and deschloro-4-hydroperoxycyclophosphamide (deschloro-4-OOH-CP) were generous gifts from Dr R.F. Borch (Department of Pharmacology, University of Rochester, USA) and Dr P.
Hilgard (ASTA-Werke Bielefeld, FRG). Both agents were dissolved in phosphate-buffered saline (PBS), pH 7.4, and 10 il of the solution were diluted in 1 ml of culture media, containing the cell suspension being tested, to obtain the final concentration.
Clonogenic cell survival assay At the end of the drug exposure, cells were washed by centrifugation through 14ml of cold medium for 10 min at 1,000g. Cellular GSH concentrations were measured by pair-ion HPLC as previously described in detail (Lee et al., 1988 (Table II) . Interestingly, most of the cell lines (four out of five) derived from squamous cell carcinomas were resistant to 4-OOH-CP even though none of them had previously been exposed to chemotherapeutics (Table I) (Lee, 1990) . These results are consistent with the accepted view that the cytotoxic action of 4-OOH-CP resides in its ability to produce DNA crosslinks (Hilton, 1984) . On the other hand, acrolien, a breakdown product of 4-OOH-CP released intracellularly is believed to be responsible for the GSH depleting action (Gurtoo et al., 1981; Lee, 1990) .
The relationship between GSH depletion and cellular sensitivity to 4-OOH-CP It was initially observed that when cells were treated with 4-OOH-CP, significant cytotoxicity was always accompanied by significant depletion of GSH content, and vice versa. This observation led us to question whether or not the degree of GSH depletion could be used as a convenient predictor of cellular sensitivity to 4-OOH-CP. A series of internally controlled experiments were performed in which both clonogenic cell survival and GSH depletion were measured on pooled cell populations treated with various concentrations of 4-OOH-CP. Figure 4 summarises the correlative data between cell survival and GSH depletion for the ovarian cancer cell lines (panel a) and the lung and squamous carcinoma cell lines (panel b). Excellent correlations exist between the degree of GSH depletion and cellular sensitivities to 4-OOH-CP. The feasibility of using GSH depletion as a predictor for chemosensitivity is illustrated by the following. At GSH depletion level of 40% of initial content, the toxicity level was -1 % cell survival (95% confidence limits = 3 x I0-5 -1.6 x 10-2). This degree of depletion can therefore be used as the 'cut-off' criterion for sensitivity since cells that were depleted to 40% of their GSH content, or lower, invariably suffered substantial cell kill. Thus cell lines that demonstrated GSH depletion to or beyond the 'cut-off' 40% point with clinically achievable equivalent concentrations of 4-OOH-CP may be considered as sensitive, and vice versa. In addition, a precise definition of sensitivity can be obtained using different concentrations of 4-OOH-CP, as illustrated by Table II) .
Discussion
The present study demonstrated that an assay technique based on the measurement of the degree of cellular GSH depletion immediately following 4-OOH-CP treatment can effectively and rapidly predict tumour response to 4-OOH-CP. Significant drug cytotoxicity was always accompanied by significant depletion of GSH content and vice versa ( Figure  4 ). For example, a dose of 4-OOH-CP that depletes GSH to 40% of initial level indicates clonogenic survival of approximately 1%. Therefore a cell type in which GSH content can be depleted to 40% or less with the maximally achievable concentration of 4-OOH-CP in patients (20) (21) (22) (23) (24) (25) ltM) (Sladek et al., 1984) may be considered 'sensitive'. One of the important features of this assay is the ease and reliability with which a complete dose-response curve can be obtained for each tumour type ( Figure 5 ). It is envisaged that the dose-response data obtained may ultimately aid in deter- mining the dose of cyclophosphamide needed to achieve a desired tumour response. This feature of the assay is of particular value because cyclophosphamide, with appropriate autologous bone marrow support, may be administered up to 15-fold above the conventional dosage (Smith et al., 1983) . With these escalated doses of cyclophosphamide, tumour response may become evident even when none was apparent at conventional dosages (Frei & Canellos, 1980; Antman et al., 1987 ). Evidence has been obtained demonstrating that the amount of the ultimate active metabolites, phosphoramide mustard (PM) and acrolein (AC), formed intracellularly from the spontaneous breakdown of 4-hydroxycyclophosphamide (4-OH-CP), is dependent on the extent of interaction between GSH and the toxic metabolites. GSH, by reacting with the intermediate metabolite aldophosphamide (AP), stabilises it from spontaneous breakdown to PM, thus minimising its cytotoxic effects. In a sensitive cell type, the GSH stabilising step is inadequate, leading to increased formation of AC and PM. The former can in turn further deplete cellular GSH. Consequently, a catastrophic cycle of GSH depletion, AP destabilisation and toxic metabolites formation is rapidly put into effect. We believe it is this mechanism that has rendered the cellular GSH status as such a sensitive indicator of tumour sensitivity to 4-OOH-CP.
Finally, a definite correlation between the steady-state cellular GSH content of tumour cell lines in vitro and their chemosensitivities to 4-OOH-CP (Figure 2 ) was also demonstrated. The considerable scatter in the data, however, does not allow the use of steady-state GSH content per se to precisely predict for sensitivity to 4-OOH-CP. Nevertheless, these data provide strong evidence that GSH plays a critical role in determining the success or failure of chemotherapy with cyclophosphamide.
